Trump announces trade deal with EU following months of negotiations
SAN JUAN CAPISTRANO - The Ensign Group , Inc. (NASDAQ:ENSG) reported second-quarter adjusted earnings that exceeded analyst expectations, as the post-acute healthcare provider benefited from improved occupancy rates and skilled services revenue. The company’s stock edged up 0.6% following the announcement.
For the quarter ended June 30, 2025, Ensign reported adjusted earnings of $1.59 per share, surpassing the analyst estimate of $1.55. Revenue reached $1.23 billion, slightly above the consensus estimate of $1.22 billion and representing an 18.5% increase from the same period last year.
The company’s same facility occupancy rate rose to 82.1%, a 2.0% improvement over the prior year quarter, while transitioning facilities saw occupancy climb to 84.0%, up 4.6% YoY. Skilled services revenue, which makes up the bulk of Ensign’s business, increased 18.4% to $1.17 billion.
"Our local teams achieved another outstanding quarter, raising the bar again for what is possible, even in a quarter where we historically have experienced more seasonality," said Barry Port, Ensign’s Chief Executive Officer. "The clinical results they achieved continue to be the primary driver of our success."
Following the strong performance, Ensign raised its 2025 earnings guidance to between $6.34 and $6.46 per diluted share, up from its previous guidance of $6.22 to $6.38. The company also increased its annual revenue guidance to $4.99 billion to $5.02 billion, up from $4.89 billion to $4.94 billion.
The company continued its expansion by adding eight new operations during the quarter, bringing the total number of acquisitions in 2024 to 52. Ensign’s portfolio now consists of 348 healthcare operations across 17 states, with 146 owned real estate assets.
The company maintained its quarterly cash dividend of $0.0625 per share, marking its 22nd consecutive year of dividend payments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.